Vetanova PEG
Delisted
PEG Ratio (Price/Earnings-to-Growth) of Vetanova (VTNA) as of Jul 31, 2026.
Get this data via API
Financial Data API
PEG
0.00
Last updated:
PEG Ratio (Price/Earnings-to-Growth) of Vetanova is 2026 0.00 . PEG Ratio (Price/Earnings-to-Growth) of Vetanova was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Vetanova Stock analysis
What does Vetanova do? Vetanova Inc is a company that specializes in the production of veterinary medicines and has its roots in the animal health industry. It was founded in 2005 by a team of experienced veterinarians with the aim of improving the treatment of pets and livestock through the development of innovative products.
Vetanova's business model is based on the manufacturing and marketing of veterinary medicines, as well as the sale of pet food and care products. The company's different divisions include both the development and production of prescription drugs and over-the-counter products, which are sold in specialty stores and online shops.
Vetanova has specialized particularly in the development of medicines against infections, parasites, and inflammation. The company relies on a combination of traditional and modern manufacturing processes to bring high-quality products to the market.
In addition to manufacturing medicines, Vetanova also offers a variety of products for the care and nutrition of pets. These include dietary supplements, pet care products, and specialized pet food tailored to their needs.
As a company dedicated to the quality of its products and the health of animals, Vetanova works closely with veterinarians and breeders to ensure that its products meet high standards. In this regard, Vetanova also strives to intensify collaboration with scientific institutions to improve and further develop the effectiveness of its products.
Animal welfare is also an important factor for Vetanova. The company advocates for the protection and well-being of animals and supports projects that help animals in need.
In summary, Vetanova is a successful and renowned company that has specialized in the development and production of veterinary medicines since 2005. The company offers a wide range of products, including both prescription and over-the-counter products, targeting both pets and livestock. Vetanova is dedicated to the health of animals and focuses on collaborating with veterinarians and breeders to improve the effectiveness and quality of its products. Animal welfare and sustainability are other important aspects emphasized by Vetanova. Vetanova is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Vetanova stock
On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Vetanova since 2006 – with annual values, charts, and detailed analysis.
Access this data via the Eulerpool API
Valuation — Vetanova
All Key Metrics — Vetanova
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth